Gilead Sciences, Inc.'s Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase 2 Study

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DENVER--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced 48-week results from a Phase 2 study (Study 102) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection. At 48 weeks, a regimen of elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/TAF 10 mg was found to be similar to StribildĀ® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) based on the percentage of patients with HIV RNA levels less than 50 copies/mL, and was associated with more favorable renal and bone safety markers. These findings were presented today in a latebreaker session (Abstract #H-1464d) at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) taking place in Denver.

Help employers find you! Check out all the jobs and post your resume.

Back to news